Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer

Paweł Krawczyk; Radosław Mlak; Tomasz Powrózek; Marcin Nicoś; Dariusz M. Kowalski; Kamila Wojas-Krawczyk; Janusz Milanowski

doi:10.5114/wo.2012.31768

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2012
vol. 16

Send email

Copy url:

abstract:

Review paper

Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer

Paweł Krawczyk

,

Radosław Mlak

,

Tomasz Powrózek

,

Marcin Nicoś

,

Dariusz M. Kowalski

,

Kamila Wojas-Krawczyk

,

Janusz Milanowski

Wspolczesna Onkol 2012; 16 (5): 401–406

DOI: https://doi.org/10.5114/wo.2012.31768

Online publish date: 2012/11/20

View full text Get citation

PlumX metrics:

Abnormalities of epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) patients consist of EGFR overexpression and EGFR (HER1) gene mutations. Structural dysfunction of the tyrosine kinase domain of EGFR is associated with the clinical response to tyrosine kinase inhibitors (TKI) in patients with NSCLC. The most common EGFR gene mutations occur as either deletions in exon 19 or as substitution L858R in exon 21 and cause a clinically beneficial response to gefinitib or erlotinib treatment. Unfortunately, the majority of patients finally develop resistance to these drugs. Acquired resistance is linked to secondary mutations localised in the EGFR gene, mainly substitution T790M in exon 20. Through intense research a few different mechanisms of resistance to reversible tyrosine kinase inhibitors have been identified: amplification of MET or IGF-1R genes, abnormalities of PTEN and mTOR proteins as well as rare mutations in EGFR and HER2 genes. Extensively investigated new drugs could be of significant efficiency in NSCLC patients with secondary resistance to reversible EGFR TKI.

keywords:

Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer

Paweł Krawczyk , Radosław Mlak , Tomasz Powrózek , Marcin Nicoś , Dariusz M. Kowalski , Kamila Wojas-Krawczyk , Janusz Milanowski

epidermal growth factor receptor, EGFR gene mutations, tyrosine kinase inhibitors, resistance mechanisms

Paweł Krawczyk

,

Radosław Mlak

,

Tomasz Powrózek

,

Marcin Nicoś

,

Dariusz M. Kowalski

,

Kamila Wojas-Krawczyk

,

Janusz Milanowski